EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 36 / Numéro 4 (Avril 2020) Med Sci (Paris), 36 4 (2020) 341-347 Références
Open Access
Numéro
Med Sci (Paris)
Volume 36, Numéro 4, Avril 2020
Page(s) 341 - 347
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020060
Publié en ligne 1 mai 2020
  1. Lacroix-Desmazes S, Navarrete A-M, André S, et al. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008 ; 112 : 240–249. [Google Scholar]
  2. Ing M, Gupta N, Teyssandier M, et al. Immunogenicity of long-lasting recombinant factor VIII products. Cell Immunol 2016 ; 301 : 40–48. [Google Scholar]
  3. Teyssandier M, André S, Gupta N, et al. Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling in vitro. Haemophilia 2013 ; 19 : 399–402. [CrossRef] [PubMed] [Google Scholar]
  4. Pfistershammer K, Stöckl J, Siekmann J, et al. Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells. Thromb Haemost 2006 ; 96 : 309–316. [CrossRef] [PubMed] [Google Scholar]
  5. Skupsky J, Zhang A-H, Su Y, et al. A role for thrombin in the initiation of the immune response to therapeutic factor VIII. Blood 2009 ; 114 : 4741–4748. [Google Scholar]
  6. Meeks SL, Cox CL, Healey JF, et al. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function. Blood 2012 ; 120 : 2512–2520. [Google Scholar]
  7. Gangadharan B, Delignat S, Ollivier V, et al. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A. J Thromb Haemost 2014 ; 12 : 2065–2069. [CrossRef] [PubMed] [Google Scholar]
  8. Lai JD, Moorehead PC, Sponagle K, et al. Concurrent influenza vaccination reduces anti-FVIII antibody responses in hemophilia A mice via chemotactic antigen competition. Blood 2016 ; 127 : 3439–3449. [Google Scholar]
  9. Platokouki H, Fischer K, Gouw SC, et al. Vaccinations are not associated with inhibitor development in boys with severe haemophilia A. Haemophilia 2018 ; 24 : 283–290. [CrossRef] [PubMed] [Google Scholar]
  10. Dimitrov JD, Dasgupta S, Navarrete A-M, et al. Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. Blood 2010 ; 115 : 2682–2685. [Google Scholar]
  11. Peyron I, Dimitrov JD, Delignat S, et al. Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice. Haemoph Off J World Fed Hemoph 2015 ; 21 : e94–e98. [CrossRef] [Google Scholar]
  12. Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010 ; 16 : 256–262. [CrossRef] [PubMed] [Google Scholar]
  13. Auerswald G, Bidlingmaier C, Kurnik K. Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients - long-term follow-up and continuing experience. Haemophilia 2012 ; 18 : e18–e20. [CrossRef] [PubMed] [Google Scholar]
  14. Sakaguchi S, Vignali DAA, Rudensky AY, et al. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013 ; 13 : 461–467. [PubMed] [Google Scholar]
  15. Hu G-L, Okita DK, Diethelm-Okita BM, et al. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003 ; 1 : 2159–2166. [CrossRef] [PubMed] [Google Scholar]
  16. Reding MT, Wu H, Krampf M, et al. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000 ; 84 : 643–652. [CrossRef] [PubMed] [Google Scholar]
  17. Meunier S, Menier C, Marcon E, et al. CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells. Blood Adv 2017 ; 1 : 1842–1847. [Google Scholar]
  18. Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J 2011 ; 25 : 2040–2048. [CrossRef] [PubMed] [Google Scholar]
  19. Delluc S, Ravot G, Maillere B. Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential. Blood 2010 ; 116 : 4542–4545. [Google Scholar]
  20. Pinto S, Michel C, Schmidt-Glenewinkel H, et al. Overlapping gene coexpression patterns in human medullary thymic epithelial cells generate self-antigen diversity. Proc Natl Acad Sci U S A 2013 ; 110 : E3497–E3505. [CrossRef] [PubMed] [Google Scholar]
  21. Hu GL, Okita DK, Diethelm-Okita BM, et al. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003 ; 1 : 2159–2166. [CrossRef] [PubMed] [Google Scholar]
  22. Kamaté C, Lenting PJ, Van Den Berg HM, et al. Depletion of CD4+ /CD25high regulatory T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals. J Thromb Haemost 2007 ; 5 : 611–613. [CrossRef] [PubMed] [Google Scholar]
  23. Algiman M, Dietrich G, Nydegger UE, et al. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992 ; 89 : 3795–3799. [CrossRef] [Google Scholar]
  24. Whelan SFJ, Hofbauer CJ, Horling FM, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013 ; 121 : 1039–1048. [Google Scholar]
  25. Hofbauer CJ, Whelan SFJ, Hirschler M, et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 2015 ; 125 : 1180–1188. [Google Scholar]
  26. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 1994 ; 94 : 1496–1505. [CrossRef] [PubMed] [Google Scholar]
  27. Sakurai Y, Shima M, Tanaka I, et al. Association of anti-idiotypic antibodies with immune tolerance induction for the treatment of hemophilia A with inhibitors. Haematologica 2004 ; 89 : 696–703. [PubMed] [Google Scholar]
  28. Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia 2002 ; 8 : 23–29. [CrossRef] [PubMed] [Google Scholar]
  29. Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016 ; 374 : 2054–2064. [Google Scholar]
  30. Gouw SC, van der Bom JG. Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007 ; 109 : 4648–4654. [Google Scholar]
  31. Hay CRM, Palmer B, Chalmers E, et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011 ; 117 : 6367–6370. [Google Scholar]
  32. Jagger AT, Shimojima Y, Goronzy JJ, et al. T regulatory cells and the immune aging process. Gerontology 2014 ; 60 : 130–137. [CrossRef] [PubMed] [Google Scholar]
  33. Pautard B D’oiron R, Li Thiao Te V, et al. Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells. J. Thromb Haemost 2011 ; 9 : 1163–1170. [CrossRef] [PubMed] [Google Scholar]
  34. Gilles JG, Desqueper B, Lenk H, et al. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996 ; 97 : 1382–1388. [CrossRef] [PubMed] [Google Scholar]
  35. Repesse Y, Peyron I, Dimitrov JD, et al. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica 2013 ; 98 : 1650–1655. [CrossRef] [PubMed] [Google Scholar]
  36. Matino D, Gargaro M, Santagostino E, et al. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest 2015 ; 125 : 3766–3781. [CrossRef] [PubMed] [Google Scholar]
  37. Moghimi B, Sack BK, Nayak S, et al. Induction of tolerance to factor VIII by transient co-administration with rapamycin. J Thromb Haemost 2011 ; 9 : 1524–1533. [CrossRef] [PubMed] [Google Scholar]
  38. Hassan S, Fijnvandraat K, van der Bom JG, et al. Preventing or eradicating factor VIII antibody formation in patients with hemophilia A: what can we learn from other disorders?. Semin Thromb Hemost 2018 ; 44 : 531–543. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.